Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 106.48 Million SEK | 1015.98% |
| 2022 | 9.54 Million SEK | -32.77% |
| 2021 | 14.19 Million SEK | -26.67% |
| 2020 | 19.35 Million SEK | 190.97% |
| 2019 | 6.65 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 114.88 Million SEK | 1.09% |
| 2024 Q1 | 113.64 Million SEK | 6.72% |
| 2023 Q2 | 109.17 Million SEK | 2373.36% |
| 2023 Q3 | 107.97 Million SEK | -1.09% |
| 2023 Q4 | 106.48 Million SEK | -1.38% |
| 2023 Q1 | 4.41 Million SEK | -53.74% |
| 2023 FY | 106.48 Million SEK | 1015.98% |
| 2022 Q3 | 5.89 Million SEK | -8.92% |
| 2022 Q1 | 6.35 Million SEK | -55.24% |
| 2022 Q2 | 6.46 Million SEK | 1.79% |
| 2022 FY | 9.54 Million SEK | -32.77% |
| 2022 Q4 | 9.54 Million SEK | 62.0% |
| 2021 FY | 14.19 Million SEK | -26.67% |
| 2021 Q4 | 14.19 Million SEK | 7330.89% |
| 2021 Q3 | 191 Thousand SEK | -84.94% |
| 2021 Q2 | 1.26 Million SEK | -64.47% |
| 2021 Q1 | 3.56 Million SEK | -81.56% |
| 2020 Q2 | 12.77 Million SEK | 12.89% |
| 2020 Q4 | 19.35 Million SEK | 95.7% |
| 2020 Q3 | 9.89 Million SEK | -22.59% |
| 2020 Q1 | 11.31 Million SEK | 70.13% |
| 2020 FY | 19.35 Million SEK | 190.97% |
| 2019 Q1 | 5.08 Million SEK | 0.0% |
| 2019 Q3 | 3.12 Million SEK | -23.92% |
| 2019 Q4 | 6.65 Million SEK | 113.21% |
| 2019 FY | 6.65 Million SEK | 0.0% |
| 2019 Q2 | 4.1 Million SEK | -19.3% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -561.533% |
| Ziccum AB (publ) | 857 Thousand SEK | -12325.554% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -2038.723% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -334.854% |
| Genovis AB (publ.) | 79.32 Million SEK | -34.25% |
| Intervacc AB (publ) | 181 Thousand SEK | -58732.597% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -416.651% |
| Active Biotech AB (publ) | 3 Million SEK | -3449.567% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -76.589% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -2029.74% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -49.123% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -1260.335% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -25014.858% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 1.946% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -3368.632% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -4027.403% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -10548.7% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 89.124% |
| Camurus AB (publ) | 24.5 Million SEK | -334.517% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -286.298% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 87.714% |
| Cyxone AB (publ) | 858 Thousand SEK | -12311.072% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -6123.67% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -189.304% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -15889.039% |
| SynAct Pharma AB | 637 Thousand SEK | -16616.954% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -12427.882% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -5946.962% |
| BioInvent International AB (publ) | 23.24 Million SEK | -358.127% |
| Alzinova AB (publ) | 800 Thousand SEK | -13210.875% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -13674.383% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -17.354% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -247.18% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 53.997% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -9936.475% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |